Preservation of allergic contact dermatitis to poison ivy (urushiol) in late hiv disease

Dermatology

Volumn 195, Issue 2, 1997, Pages 145-149

  Smith, K J ^a   Skelton, H G ^c   Nelson, A ^c   Wagner, K F ^a   Hockley, B E ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Allergic contact dermatitis; HIV disease; Immunotherapy; Urushiol

Indexed keywords

CYTOKINE; URUSHIOL;

ARTICLE; BLISTER; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DISEASE COURSE; EFFECTOR CELL; ERYTHEMA; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; POISON IVY; PRIORITY JOURNAL; SKIN ALLERGY;

CATECHOLS; DERMATITIS, ALLERGIC CONTACT; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; MALE; PATCH TESTS; PLANTS, TOXIC; TOXICODENDRON;

EID: 0030746895     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000245718     Document Type: Article

References (26)

1. Johnson RA. Dover JS: Cutaneous manifestations of human immunodeficiency virus disease: in Fitzpatrick TB, Eisen AZ. Wolf K. Freedberg IM, Austen KF (eds): Dermatology in General Medicine. New York. McGraw-Hill, 1993, pp 2637-2699.
2. Coldrion BM. Bergstresser PR: Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989:125:357-361.
3. Michael NL. Burge DS: Natural history of human immunodeficiency virus infection. Dermatol Clin 1991:9:429-441.
4. Birx DL. Brundage J. Larson K. Engler R. Smith L, Squre E. Carpcnier G. Sullivan M. Rhoads J, Oster C. Burke D: The prognostic utility of delayed-lype hypersensitivity skin testing in the evaluation of HIV-infected patients. A Acquir Immune Defic Syndr 1993:6: 1248-1257.
5. Gordin FM. Hartigan PM. Klimas NG. Zolla-Pasner SB. Simberkoff MS. Hamilton JD: Dc-layed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. J Infect Dis 1994:169:893-897.
6. Kalish RS. Johnson KL: Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J Immunol 1990:145: 3706-3713.
7. Gocinski BL. Tigelaar RE: Roles of CD4+ and CD8+ cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion. J Immunol 1990:144:4121-4128.
8. Kalish RS: Antigen processing: The gateway to the immune response. J Am Acad Dermatol 1995:32:640-652.
9. Stingl G. Rappersberger K. Tsehaehler E. Gartner S, Groh V. Mann DL. Wolff K. Popovic M: Langerhans cells in HIV-I infection. J Am Acad Dermatol 1990:22:1210-1217.
10. Henry M. Ullhman A. Ballaun C. Stingl G. Tsehaehler E: Epidermal Langerhans cells of AIDS patients express HIV-I regulatory and structural genes. J Invest Dermatol 1994:103: 593-596.
11. Blauvelt A. Katz SI: The skin as target, vector, and effector organ in human immunodeficiency virus disease. J Incest Dermatol 1995; 105:122S-126S.
12. Strieker RB. Zhu YS. Elswood BE. Dumlao C. Van Elk J. Berger TG. Tappero J. Epstein WL. Kiprov DD: Pilot study of topical dinitro-chlorobenzene (DNCB) in human immunodeficiency virus infection. Immunol Lett 1993; 36:1-6.
13. Epstein WL. StricklerRB: Immunomodulation by allergic contact sensititzation: The dinitro-chlorobenzene story. Am J Contact Dermatol 1995:6:117-121.
14. Strieker RB. Goldberg B. Mills LB. Epstein WL: Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene. J Am Acad Dermatol 1995:33:608-611.
15. Mosemann TR. Coffman RE: Till and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989:7:145-173.
16. ICi Clerici M. Sliearer GM: A Thl toTh2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993:14:107-110.
17. Barccllini W. Rizardi GP. Borghi O. Fain C. Lazzarin A. Mcroni PI.: Thl andTh2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994: 8:757-762.
18. Romagnani S. Del Prete G. Ravina MA. Annunziato F. De Carli M. Mazzetti M. Piccinni MP. Delios MM. Paronchi P. Sampoginaro S. Maggi E: Role of Thl/Th2 cytokines in HIV infection. Immunol Rev 1994:140:73-92.
19. Enk AH. Angeloni VL. Katz SI: Inhibition of Langerhans cell antigen-presenting function by IL-10: A role for IL-10 in induction of tolerance. J Immunol 1993:151:2390-2398.
20. Ascher MS. Sheppard IIW: AIDS as immune system activation. II. The pancrgic imnesia hypothesis. J Acquir Immune Delic Syndr 1990; 3:177-191.
21. Del Prete G. Maggi E. Pizzolo G. Romagnani S: CD30. Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 1995:16:76-80.
22. Maggi E. Mazzetti M. Ravina A. Annunziato F. De Carli M. Piccinni MP. Manetti R. Carbonari M. Pescc AM. Del Prete G. Romagnani S: Ability of HIV to promote a Thl to ThO shift and replicate preferentially in Th2 and ThO cells. Science 1994:265:244-248.
23. Romagnani S. Maggi E, Del Prete G: Tenth anniversary perspectives on AIDS: An alternative view of the Thl/Th2 switch hypothesis in HIV infection. AIDS Res Hum Retrovir 1994; 10:iii-ix.
24. Mackewicz CE. Ortega HW. Levy JA: CD8+ anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991:87:1462-1466.
25. Happlc R: The potential hazards of dinitro-chlorobenzene (DNCB). Arch Dermatol 1985; 121:330-332.
26. Dunagin WG: Potential hazards of dinitro-chlorobenzene (DNCB) disputed (letter). Arch Dermatol 1986:122:11-13.